Skip to content
POM-V Prescription Required Companion Animal

Caniphedrin 50 mg Tablets for Dogs

Active ingredient: Ephedrine Hydrochloride

Form

Tablet

Species

Dogs

Manufacturer

VetViva Richter GmbH

VMD MA No.

57446/4020

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Ephedrine Hydrochloride

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Caniphedrin 50 mg Tablets for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

The tablets can be divided into 2 equal parts to ensure accurate dosing.
The recommended starting dose is 2 mg ephedrine hydrochloride (corresponding to
1.64 mg of ephedrine) per kg bodyweight (BW), equivalent to 1 tablet per 25 kg BW,
per day during the first 10 days of treatment. The daily dose may be divided. Once
the desired effect has been achieved, the dose can be reduced to one half or less.
Based on the observed effect and taking into account the occurrence of adverse
effects, the individual dose should be adjusted to find the lowest effective dose. The
lowest effective dose should be maintained for long-term treatment. In case of a
relapse, the dose should be increased to 2 mg ephedrine hydrochloride per kg BW
AN: 01317/2024 & 01318/2024
again. Once the effective dose has been established, dogs should still be monitored
at regular intervals.
This tablet strength is not appropriate for dogs weighing less than 12.5 kg
(recommended starting dose of 2 mg/kg).
Do not use in dogs with cardiovascular disease (i.e. cardiomyopathy, tachycardic
arrhythmia, hypertension), hyperthyroidism, diabetes mellitus, impaired renal function or
glaucoma.
Do not use concurrently with halogenated narcotics such as halothane or
methoxyflurane (see section 3.8).
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
AN: 01317/2024 & 01318/2024
Dogs:
Rare
(1 to 10 animals / 10 000 animals treated):
Rapid pulse rate
, Ventricular arrhythmia
;
Excitation
.
Undetermined frequency
(cannot be estimated from the available
data):
Tachycardia
, Atrial fibrillation
, Increased
heart rate
, Peripheral vasoconstriction
;
Not sleeping
, Anxiety
;
Muscle tremor
, Mydriasis
;
AN: 01317/2024 & 01318/2024
Pulmonary disorder (bronchodilatation and
decrease of mucus release in the
respiratory mucosal membranes)
;
Digestive tract hypomotility
.
These symptoms disappear following dose reduction or termination of treatment.
Due to the pharmacological properties of ephedrine these effects can occur at the
recommended therapeutic dose.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.
It is not appropriate to use the veterinary medicinal product for the behavioural cause of
inappropriate urination.
In bitches less than 1 year old the possibility of anatomical disorders contributing to
incontinence should be considered prior to treatment.
It is important to identify any underlying disease causing Polyuria/Polydipsia (PU/PD)
which may be falsely diagnosed as urinary incontinence.

Special precautions for safe use in the target species:
The dog’s cardiovascular functionality should be carefully assessed before the start of
the treatment with the veterinary medicinal product and it should be periodically
monitored during the treatment.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
People with known hypersensitivity to ephedrine should avoid contact with the veterinary
medicinal product.
Ephedrine hydrochloride could be toxic if ingested and ingestion may be fatal, especially
to children. Adverse effects may include insomnia and nervousness, dizziness,
headache, increased blood pressure, increased sweating and nausea.
To avoid accidental ingestion, particularly by a child, the veterinary medicinal product
must be administered out of the sight of children. Unused tablet parts should be returned
to the open blister space and inserted back into the carton and kept in a safe place out
of the sight and reach of children.
In case of accidental ingestion, most importantly by children, seek medical advice
immediately and show the package leaflet or the label to the physician.
It is strongly recommended that pregnant women should wear impermeable gloves
when handling the tablets.
Wash hands thoroughly after administration of the veterinary medicinal product.
Special precautions for the protection of the environment:
Not applicable.
The potency of ephedrine and the risk of adverse reactions may be increased when
administered together with methylxanthines and sympathomimetics.
Ephedrine may enhance glucocorticoid metabolism.
Concomitant use with MAO-inhibitors may cause hypertension.
Ephedrine may increase the risk for theophylline toxicity.
There is a risk of cardiac arrhythmia when combined with cardiac glycosides (e.g.
digoxin), quinine, tricyclic antidepressants and halogenated narcotics (see section
3.3).
Substances leading to an increase in pH of the urine are able to prolong the
excretion of ephedrine, which may lead to an increased risk of adverse reactions.
Substances leading to a decrease in pH of the urine are able to accelerate the
excretion of ephedrine, which may lead to decreased efficacy.
Vascular constrictions can occur after concomitant treatment with ergot alkaloids and
oxytocin.
Sympatholytics may decrease the efficacy of ephedrine.
Keep the blisters in the outer carton in order to protect from light. Do not refrigerate
or freeze.
Unused divided tablets should be returned to the blister and used in the subsequent
dose.
Not applicable.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance
Same active ingredient

Other Products Containing Ephedrine Hydrochloride

These products share the same active ingredient and may be suitable alternatives. Always consult your vet.

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.